+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Viral Vector Production (Research-Use) - Global Strategic Business Report

  • PDF Icon

    Report

  • 74 Pages
  • June 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6071815
This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Viral Vector Production (Research-Use) market.

Global Viral Vector Production (Research-Use) Market - Key Trends & Drivers Summarized

Why Is Viral Vector Production Critical for Biomedical Research?

Viral vector production has become a crucial component of biomedical research, particularly in the development of gene therapies, vaccines, and cancer treatments. Viral vectors serve as delivery systems for genetic material, enabling scientists to introduce, modify, or replace genes within cells to study disease mechanisms and develop targeted therapies. The increasing prevalence of genetic disorders, infectious diseases, and cancer has fueled the demand for high-quality viral vectors for preclinical and clinical research. With advancements in cell and gene therapy, researchers are leveraging viral vectors such as lentiviruses, adeno-associated viruses (AAVs), and retroviruses to develop innovative treatments for conditions that were previously considered untreatable. The ongoing development of mRNA-based vaccines and immunotherapies has further highlighted the importance of viral vector production, as researchers require scalable and efficient manufacturing processes to accelerate drug discovery and development.

What Technological Innovations Are Transforming Viral Vector Production?

The field of viral vector production has seen significant advancements, improving efficiency, scalability, and safety in research applications. One of the most notable innovations is the use of suspension cell culture systems, which enable large-scale viral vector production in bioreactors, reducing costs and improving consistency. Additionally, the development of high-yield transfection reagents and optimized plasmid designs has enhanced viral vector titers, allowing researchers to produce higher-quality vectors with increased stability. Automation and AI-driven process optimization are also revolutionizing viral vector manufacturing by minimizing variability and streamlining production workflows. CRISPR-based genome editing tools are further enhancing viral vector engineering, enabling researchers to create more precise and efficient gene delivery systems. Moreover, improvements in purification technologies, such as chromatography and ultracentrifugation, have enhanced vector purity and potency, ensuring higher efficacy in gene therapy research.

What Challenges Are Limiting the Expansion of Viral Vector Production?

Despite its critical role in biomedical research, viral vector production faces several challenges that impact scalability and accessibility. One of the primary obstacles is the complexity of manufacturing viral vectors, as production requires specialized cell culture facilities, biosafety protocols, and rigorous quality control measures. High production costs and limited scalability remain key barriers, particularly for smaller research institutions that lack the infrastructure to produce viral vectors in large quantities. Additionally, regulatory challenges associated with viral vector production, including safety concerns and compliance with good manufacturing practices (GMP), can slow down the research-to-market pipeline. Stability and storage limitations also pose a challenge, as some viral vectors have short shelf lives, requiring specialized storage conditions to maintain potency. Addressing these challenges requires continued investment in scalable manufacturing technologies, standardized regulatory frameworks, and cost-effective production strategies to ensure broader accessibility of viral vectors for research use.

What Factors Are Driving the Growth of the Viral Vector Production (Research-Use) Market?

The growth in the viral vector production (research-use) market is driven by several factors, including the rising demand for gene therapies, advancements in vaccine development, and increasing investments in biomedical research. The growing prevalence of genetic disorders and infectious diseases has fueled the need for innovative treatment approaches, prompting researchers to develop and refine viral vector-based therapies. The expansion of personalized medicine and regenerative therapies has further accelerated the adoption of viral vectors in preclinical and clinical research. Additionally, government funding and private sector investments in biotechnology have supported the development of scalable viral vector manufacturing platforms, facilitating faster research and drug development timelines. The rapid advancement of CRISPR and genome-editing technologies has also contributed to market growth, as researchers seek efficient gene delivery tools for precision medicine applications. As demand for viral vectors continues to rise, ongoing technological advancements and process optimization efforts are expected to drive market expansion, ensuring the continued progress of gene and cell therapy research.

Report Scope

The report analyzes the Viral Vector Production (Research-Use) market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Vector Type (Adeno-associated Virus, Lentivirus, Adenovirus, Retrovirus, Others); Application (Cell & Gene Therapy Development, Vaccine Development, Pharma & Biopharma Discovery, Biomedical Research); End-Use (Pharma & Biopharma Companies, Research Institutes)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Viral Vector Production (Research-Use) Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Viral Vector Production (Research-Use) Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Viral Vector Production (Research-Use) Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AGC Biologics, Batavia Biosciences, BioNTech IMFS GmbH, Catalent Inc., Cobra Biologics (Charles River Laboratories) and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 44 Featured):

  • AGC Biologics
  • Batavia Biosciences
  • BioNTech IMFS GmbH
  • Catalent Inc.
  • Cobra Biologics (Charles River Laboratories)
  • FUJIFILM Diosynth Biotechnologies
  • Genezen
  • Lonza Group
  • Merck KGaA
  • Miltenyi Biotec
  • Novasep Holdings SAS
  • Oxford Biomedica
  • REGENXBIO Inc.
  • SIRION Biotech GmbH
  • Takara Bio Inc.
  • Thermo Fisher Scientific
  • uniQure N.V.
  • Virovek
  • Waisman Biomanufacturing
  • WuXi AppTec

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

  • Tariff-adjusted market forecasts by region and segment
  • Analysis of cost and supply chain implications by sourcing and trade exposure
  • Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

  • Finalized tariff impacts and new trade agreement effects
  • Updated projections reflecting global sourcing and cost shifts
  • Expanded country-specific coverage across the industry

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Viral Vector Production (Research-Use) - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Expanding Role of Viral Vectors in Gene Therapy Research Throws the Spotlight On Custom Vector Manufacturing
  • Surging Demand for Preclinical Gene Delivery Studies Drives Adoption of Scalable Research-Grade Viral Vectors
  • Growth in Academic and Translational Research Accelerates Demand for Customizable and Cost-Efficient Viral Platforms
  • Increased Funding for Cell and Gene Therapy Projects Expands Addressable Market Opportunity for Research-Use Vectors
  • Technological Advances in Transfection and Packaging Protocols Strengthen Business Case for High-Yield Production
  • Rising Use of Adeno-Associated and Lentiviral Vectors Spurs Growth in Non-GMP Research Settings
  • Integration of CRISPR and Gene Editing Applications Drives Demand for High-Fidelity Viral Vectors
  • Emergence of Modular Vector Design Technologies Enhances Flexibility and Reduces Turnaround Time
  • Growing Adoption of Suspension Cell Culture Systems Accelerates Shift Toward Scalable Manufacturing Platforms
  • Advancements in Purification and Concentration Methods Strengthen Competitive Advantage in Research-Use Markets
  • Expansion of Contract Research Organizations (CROs) Bolsters Outsourced Vector Development Capabilities
  • Shift Toward Personalized and Targeted Research Models Drives Demand for Custom Viral Constructs
  • Regulatory Loosening for Research-Only Vectors Streamlines Academic and Preclinical Development Pipelines
  • Increased Interdisciplinary Research Collaborations Propel Demand for Versatile Viral Vector Toolkits
  • Adoption of High-Throughput Screening Technologies Expands Use of Viral Vectors in Functional Genomics
  • Emerging Interest in Non-Human Primate Models Drives Demand for Species-Specific Viral Vector Solutions
  • Transition from 2D to 3D Cell Culture Systems Spurs Innovation in Vector Delivery Mechanisms
  • Growing Complexity of Experimental Therapeutics Throws the Spotlight On Multi-Gene Delivery Vectors
  • Rising Emphasis on Safety and Transduction Efficiency Strengthens Demand for Next-Gen Research Vectors
  • Widening Gap Between Research-Grade and GMP-Grade Vector Capabilities Creates Strategic Differentiation Opportunities
  • Globalization of Research and Cross-Border Collaborations Drives Growth in Multi-Regional Vector Supply Chains
  • Expansion of Incubator Labs and Biotech Accelerators Generates New Market for Ready-to-Use Research Vectors
  • Growing Public and Private Investment in Viral Vector Research Programs Fuels Long-Term Market Sustainability
4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Viral Vector Production (Research-Use) Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Viral Vector Production (Research-Use) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Viral Vector Production (Research-Use) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Viral Vector Production (Research-Use) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Adeno-associated Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Adeno-associated Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Adeno-associated Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Lentivirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Lentivirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Lentivirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Adenovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Adenovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Adenovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Retrovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Retrovirus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Retrovirus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Pharma & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Cell & Gene Therapy Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Cell & Gene Therapy Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Cell & Gene Therapy Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Vaccine Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Vaccine Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Vaccine Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Pharma & Biopharma Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Pharma & Biopharma Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Pharma & Biopharma Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Biomedical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Biomedical Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Biomedical Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • CANADA
  • JAPAN
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • CHINA
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • EUROPE
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • FRANCE
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • GERMANY
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • ITALY
  • UNITED KINGDOM
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • SPAIN
  • RUSSIA
  • REST OF EUROPE
  • ASIA-PACIFIC
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • AUSTRALIA
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • INDIA
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA
  • Viral Vector Production (Research-Use) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AGC Biologics
  • Batavia Biosciences
  • BioNTech IMFS GmbH
  • Catalent Inc.
  • Cobra Biologics (Charles River Laboratories)
  • FUJIFILM Diosynth Biotechnologies
  • Genezen
  • Lonza Group
  • Merck KGaA
  • Miltenyi Biotec
  • Novasep Holdings SAS
  • Oxford Biomedica
  • REGENXBIO Inc.
  • SIRION Biotech GmbH
  • Takara Bio Inc.
  • Thermo Fisher Scientific
  • uniQure N.V.
  • Virovek
  • Waisman Biomanufacturing
  • WuXi AppTec